Primary Sjögren's syndrome: Time for prospective cohorts

Current Pharmaceutical Biotechnology

Volumn 13, Issue 10, 2012, Pages 2022-2025

  Gottenberg, Jacques Eric ^a   Mariette, Xavier ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Cohort; Disease activity; Marker; Prospective; Sj gren's syndrome

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; DNA; HYDROXYCHLOROQUINE; METHOTREXATE; PILOCARPINE; PLACEBO; PREDNISONE; RITUXIMAB; RNA;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL FEATURE; COMORBIDITY; DISEASE ACTIVITY; GENETIC PREDISPOSITION; HUMAN; LYMPHOMA; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY SJOEGREN SYNDROME; PROGNOSIS; RISK FACTOR; SJOEGREN SYNDROME;

BIOLOGICAL MARKERS; COHORT STUDIES; FRANCE; GREAT BRITAIN; HUMANS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84862489975     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802273128     Document Type: Article

References (31)

1. Gottenberg, J.E. Primary Sjogren's syndrome: pathophysiological, clinical and therapeutic advances. Joint Bone Spine 2009, 76(6), 591-594.
2. Fox, R.I. Sjogren's syndrome. Lancet 2005, 366(9482), 321-331.
3. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61(6), 554-558.
4. Seror, R.; Ravaud, P.; Bowman, S.J.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010, 69(6), 1103-1109.
5. Sankar, V.; Brennan, M.T.; Kok, M.R.; Leakan, R.A.; Smith, J.A.; Manny, J.; Baum, B.J.; Pillemer, S.R. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004, 50(7), 2240-2245.
6. Mariette, X.; Ravaud, P.; Steinfeld, S.; Baron, G.; Goetz, J.; Hachulla, E.; Combe, B.; Puechal, X.; Pennec, Y.; Sauvezie, B.; Perdriger, A.; Hayem, G.; Janin, A.; Sibilia, J. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50(4), 1270-1276.
7. Dass, S.; Bowman, S.J.; Vital, E.M.; Ikeda, K.; Pease, C.T.; Hamburger, J.; Richards, A.; Rauz, S.; Emery, P. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67(11), 1541-1544.
8. Meijer, J.M.; Meiners, P.M.; Vissink, A.; Spijkervet, F.K.; Abdulahad, W.; Kamminga, N.; Brouwer, E.; Kallenberg, C.G.; Bootsma, H. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62(4), 960-968.
9. Baimpa, E.; Dahabreh, I.J.; Voulgarelis, M.; Moutsopoulos, H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88(5), 284-293.
10. Zhang, W.; Feng, S.; Yan, S.; Zhao, Y.; Li, M.; Sun, J.; Zhang, F.C.; Cui, Q.; Dong, Y. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010, 49(3), 571-577.
11. Theander, E.; Henriksson, G.; Ljungberg, O.; Mandl, T.; Manthorpe, R.; Jacobsson, L.T. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65(6), 796-803.
12. Ioannidis, J.P.; Vassiliou, V.A.; Moutsopoulos, H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002, 46(3), 741-747.
13. Skopouli, F.N.; Dafni, U.; Ioannidis, J.P.; Moutsopoulos, H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29(5), 296-304.
14. Kassan, S.S.; Thomas, T.L.; Moutsopoulos, H.M.; Hoover, R.; Kimberly, R.P.; Budman, D.R.; Costa, J.; Decker, J.L.; Chused, T.M. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89(6), 888-892.
15. Ramos-Casals, M.; Solans, R.; Rosas, J.; Camps, M.T.; Gil, A.; Del Pino-Montes, J.; Calvo-Alen, J.; Jimenez-Alonso, J.; Mico, M.L.; Beltran, J.; Belenguer, R.; Pallares, L. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008, 87(4), 210-219.
16. Tzioufas, A.G.; Boumba, D.S.; Skopouli, F.N.; Moutsopoulos, H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996, 39(5), 767-772.
17. Theander, E.; Manthorpe, R.; Jacobsson, L.T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004, 50(4), 1262-1269.
18. Stevens, R.J.; Hamburger, J.; Ainsworth, J.R.; Holmes, G.; Bowman, S.J. Flares of systemic disease in primary Sjogren's syndrome. Rheumatology (Oxford) 2005, 44(3), 402-403.
19. Franklin, J.; Lunt, M.; Bunn, D.; Symmons, D.; Silman, A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006, 65(5), 617-622.
20. Vitali, C.; Palombi, G.; Baldini, C.; Benucci, M.; Bombardieri, S.; Covelli, M.; Del Papa, N.; De Vita, S.; Epis, O.; Franceschini, F.; Gerli, R.; Govoni, M.; Bongi, S.M.; Maglione, W.; Migliaresi, S.; Montecucco, C.; Orefice, M.; Priori, R.; Tavoni, A.; Valesini, G. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007, 56(7), 2223-2231.
21. Barry, R.J.; Sutcliffe, N.; Isenberg, D.A.; Price, E.; Goldblatt, F.; Adler, M.; Canavan, A.; Hamburger, J.; Richards, A.; Regan, M.; Gadsby, K.; Rigby, S.; Jones, A.; Mathew, R.; Mulherin, D.; Stevenson, A.; Nightingale, P.; Rauz, S.; Bowman, S.J. The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome. Rheumatology (Oxford) 2008, 47(8), 1193-1198.
22. Bowman, S.J.; Sutcliffe, N.; Isenberg, D.A.; Goldblatt, F.; Adler, M.; Price, E.; Canavan, A.; Hamburger, J.; Richards, A.; Rauz, S.; Regan, M.; Gadsby, K.; Rigby, S.; Jones, A.; Mathew, R.; Mulherin, D.; Stevenson, A.; Nightingale, P. Sjogren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome. Rheumatology (Oxford) 2007, 46(12), 1845-1851.
23. Bowman, S.J.; Hamburger, J.; Richards, A.; Barry, R.J.; Rauz, S. Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory. Rheumatology (Oxford) 2009, 48(2), 140-143.
24. Daniels, T.E.; Criswell, L.A.; Shiboski, C.; Shiboski, S.; Lanfranchi, H.; Dong, Y.; Schiodt, M.; Umehara, H.; Sugai, S.; Challacombe, S.; Greenspan, J.S. An early view of the international Sjogren's syndrome registry. Arthritis Rheum 2009, 61(5), 711-714.
25. Whitcher, J.P.; Shiboski, C.H.; Shiboski, S.C.; Heidenreich, A.M.; Kitagawa, K.; Zhang, S.; Hamann, S.; Larkin, G.; McNamara, N.A.; Greenspan, J.S.; Daniels, T.E. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 2010, 149(3), 405-415.
26. Gottenberg, J.E.; Busson, M.; Cohen-Solal, J.; Lavie, F.; Abbed, K.; Kimberly, R.P.; Sibilia, J.; Mariette, X. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis 2005, 64(7), 1050-1055.
27. Gottenberg, J.E.; Aucouturier, F.; Goetz, J.; Sordet, C.; Jahn, I.; Busson, M.; Cayuela, J.M.; Sibilia, J.; Mariette, X. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007, 66(1), 23-27.
28. Gottenberg, J.E.; Cagnard, N.; Lucchesi, C.; Letourneur, F.; Mistou, S.; Lazure, T.; Jacques, S.; Ba, N.; Ittah, M.; Lepajolec, C.; Labetoulle, M.; Ardizzone, M.; Sibilia, J.; Fournier, C.; Chiocchia, G.; Mariette, X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006, 103(8), 2770-2775.
29. Bauer, J.W.; Petri, M.; Batliwalla, F.M.; Koeuth, T.; Wilson, J.; Slattery, C.; Panoskaltsis-Mortari, A.; Gregersen, P.K.; Behrens, T.W.; Baechler, E.C. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60(10), 3098-3107.
30. Miceli-Richard, C.; Gestermann, N.; Ittah, M.; Comets, E.; Loiseau, P.; Puechal, X.; Hachulla, E.; Gottenberg, J.E.; Lebon, P.; Becquemont, L.; Mariette, X. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 2009, 60(7), 1991-1997.
31. Gestermann, N.; Mekinian, A.; Comets, E.; Loiseau, P.; Puechal, X.; Hachulla, E.; Gottenberg, JE.; Mariette, X.; Miceli-Richard, C. STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun, 2010, 11(5), 432-8.